Annonce • May 14
FamiCord AG, Annual General Meeting, Jun 24, 2026 FamiCord AG, Annual General Meeting, Jun 24, 2026, at 11:00 W. Europe Standard Time. Reported Earnings • May 05
Full year 2025 earnings released: €0.26 loss per share (vs €0.70 loss in FY 2024) Full year 2025 results: €0.26 loss per share (improved from €0.70 loss in FY 2024). Revenue: €88.2m (up 7.3% from FY 2024). Net loss: €4.61m (loss narrowed 62% from FY 2024). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. New Risk • May 03
New major risk - Revenue and earnings growth Earnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€77.4m market cap, or US$90.7m). New Risk • Mar 09
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €83.3m (US$96.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Reported Earnings • Nov 23
Third quarter 2025 earnings released: EPS: €0.074 (vs €0.06 in 3Q 2024) Third quarter 2025 results: EPS: €0.074 (up from €0.06 in 3Q 2024). Revenue: €22.8m (up 2.5% from 3Q 2024). Net income: €1.24m (up 14% from 3Q 2024). Profit margin: 5.4% (up from 4.9% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Annonce • Nov 22
FamiCord AG Confirms Earnings Guidance for the Financial Year 2025 FamiCord AG confirmed earnings guidance for the financial year 2025. On the basis of the performance in the first nine months of 2025, the Management Board looks to the remaining months of the year with confidence. The combination of solid revenue growth with attractive gross margins, a strong improvement in EBITDA, a positive operating cash flow despite the shift towards recurring revenues and a stable financial position provides a robust foundation. Against this backdrop, the Management Board confirms its outlook for the full year 2025, which continues to assume revenues of between EUR 85 million and EUR 95 million. Price Target Changed • Sep 03
Price target increased by 19% to €7.50 Up from €6.30, the current price target is provided by 1 analyst. New target price is 10% above last closing price of €6.80. Stock is up 45% over the past year. The company is forecast to post earnings per share of €0.04 next year compared to a net loss per share of €0.70 last year. New Risk • Aug 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Annonce • May 16
FamiCord AG, Annual General Meeting, Jun 25, 2025 FamiCord AG, Annual General Meeting, Jun 25, 2025, at 10:00 W. Europe Standard Time. Price Target Changed • May 06
Price target increased by 8.3% to €6.50 Up from €6.00, the current price target is provided by 1 analyst. New target price is 65% above last closing price of €3.94. Stock is down 17% over the past year. The company is forecast to post a net loss per share of €0.01 next year compared to a net loss per share of €0.70 last year. Reported Earnings • May 04
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: €0.70 loss per share (further deteriorated from €0.12 loss in FY 2023). Revenue: €82.2m (up 6.6% from FY 2023). Net loss: €12.1m (loss widened €10.3m from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Major Estimate Revision • Dec 01
Consensus estimates of losses per share improve by 38% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €81.0m to €82.0m. EPS estimate increased from -€0.08 per share to -€0.05 per share. Healthcare industry in Germany expected to see average net income decline 4.2% next year. Consensus price target of €6.30 unchanged from last update. Share price was steady at €4.12 over the past week. New Risk • Nov 25
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 17% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 17% per year for the foreseeable future. Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€72.5m market cap, or US$75.5m). Reported Earnings • Sep 01
Second quarter 2024 earnings released: €0.10 loss per share (vs €0.07 loss in 2Q 2023) Second quarter 2024 results: €0.10 loss per share (further deteriorated from €0.07 loss in 2Q 2023). Revenue: €19.5m (up 6.0% from 2Q 2023). Net loss: €1.41m (loss widened 19% from 2Q 2023). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings. Major Estimate Revision • Jun 09
Consensus estimates of losses per share improve by 33% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €79.1m to €81.0m. EPS estimate increased from -€0.12 per share to -€0.08 per share. Healthcare industry in Germany expected to see average net income growth of 16% next year. Consensus price target up from €5.30 to €6.00. Share price rose 3.0% to €4.86 over the past week. Reported Earnings • Jun 05
First quarter 2024 earnings released: €0.05 loss per share (vs €0.18 loss in 1Q 2023) First quarter 2024 results: €0.05 loss per share (improved from €0.18 loss in 1Q 2023). Revenue: €18.6m (up 3.6% from 1Q 2023). Net loss: €785.0k (loss narrowed 73% from 1Q 2023). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings. Price Target Changed • Jun 05
Price target increased by 15% to €6.00 Up from €5.21, the current price target is provided by 1 analyst. New target price is 22% above last closing price of €4.92. Stock is down 20% over the past year. The company is forecast to post a net loss per share of €0.08 next year compared to a net loss per share of €0.12 last year. Breakeven Date Change • May 02
No longer forecast to breakeven The analyst covering VITA 34 no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €1.05m in 2024. New forecast suggests the company will make a loss of €1.50m in 2025. New Risk • Apr 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€1.7m net loss in 2 years). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€78.8m market cap, or US$83.8m). New Risk • Apr 04
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €25m Forecast net loss in 2 years: €1.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€1.7m net loss in 2 years). Shareholders have been diluted in the past year (10% increase in shares outstanding). New Risk • Feb 12
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€86.3m market cap, or US$93.1m). Reported Earnings • Nov 26
Third quarter 2023 earnings released: €0.10 loss per share (vs €0.02 loss in 3Q 2022) Third quarter 2023 results: €0.10 loss per share (further deteriorated from €0.02 loss in 3Q 2022). Revenue: €20.4m (up 9.4% from 3Q 2022). Net loss: €1.62m (loss widened €1.41m from 3Q 2022). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 1.6% decline forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance. Reported Earnings • Sep 01
Second quarter 2023 earnings released: €0.07 loss per share (vs €0.30 loss in 2Q 2022) Second quarter 2023 results: €0.07 loss per share (improved from €0.30 loss in 2Q 2022). Revenue: €18.4m (up 10% from 2Q 2022). Net loss: €1.19m (loss narrowed 74% from 2Q 2022). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance. Major Estimate Revision • Jul 05
Consensus EPS estimates fall by 28%, revenue upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €75.0m to €76.0m. Forecast EPS reduced from -€0.09 to -€0.115 per share. Healthcare industry in Germany expected to see average net income growth of 15% next year. Consensus price target down from €9.25 to €6.81. Share price rose 2.2% to €5.64 over the past week. New Risk • Jun 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (€83.6m market cap, or US$91.2m). New Risk • Jun 13
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €83.6m (US$90.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Reported Earnings • Jun 02
First quarter 2023 earnings released: €0.18 loss per share (vs €0.18 loss in 1Q 2022) First quarter 2023 results: €0.18 loss per share (in line with 1Q 2022). Revenue: €17.9m (up 16% from 1Q 2022). Net loss: €2.89m (loss widened 2.8% from 1Q 2022). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance. Annonce • May 12
Vita 34 Ag Starts Recruitment for Clinical Trial with Car-T Drug Candidate Vita 34 AG has started enrollment in Phase I of the Tarcidomgen Kimleucel clinical trial. The drug candidate is an anti-CD19 CAR-T, a chimeric antigen receptor, and the first candidate in Vita 34's Cell & Gene Therapy (CGT) portfolio. After recent clearance by the responsible authorities and the responsible ethics committee, the start of the clinical trial under the name CARLA and the recruitment of the first patient ("First Patient In") is imminent. A total of up to ten patients are expected to be recruited for Phase I of the study, which is the usual number for this type of drug. The recruitment will take place via two clinical centers in Poland. The Management Board of Vita 34 AG expects Phase I to be completed by the end of 2023. The costs related with this phase of the trial have already taken into consideration in the guidance published for 2023. The principal investigator of the CARLA study is Prof. Grzegorz Basak, Professor and Chairman of the Department of Hematology, Transplantation and Internal Medicine at the University Hospital of Warsaw Medical University. Tarcidomgen Kimlucel is being developed through FamiCordTx, a subsidiary of Vita 34 AG that aims to develop proprietary CAR-T drug therapies. FamiCordTx has secured an exclusive license from a U.S. supplier for this purpose in the past and has optimized the technology according to European GMP standards. CAR-T therapy uses a patient's own T cells, which are genetically engineered in a laboratory to produce a protein called a chimeric antigen receptor (CAR). When the modified T-cells are returned to the patient, the CAR enables the T- cells to seek out and destroy cancer cells wherever they are in the body. According to a report by Allied Market Research, the global CAR-T cell therapy market was valued USD 1,7 billion in 2021 and is expected to reach USD 6.1 billion by 2031. Reported Earnings • May 02
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: €1.71 loss per share (further deteriorated from €0.63 loss in FY 2021). Revenue: €68.9m (up 143% from FY 2021). Net loss: €27.1m (loss widened €23.4m from FY 2021). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 100 percentage points per year, which is a significant difference in performance. Major Estimate Revision • Dec 01
Consensus estimates of losses per share improve by 10% The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from €66.5m to €67.7m. EPS estimate increased from -€0.59 per share to -€0.53 per share. Healthcare industry in Germany expected to see average net income decline 6.2% next year. Consensus price target of €10.50 unchanged from last update. Share price fell 7.6% to €8.32 over the past week. Reported Earnings • Nov 24
Third quarter 2022 earnings released: €0.02 loss per share (vs €0.11 profit in 3Q 2021) Third quarter 2022 results: €0.02 loss per share (down from €0.11 profit in 3Q 2021). Revenue: €18.7m (up 230% from 3Q 2021). Net loss: €209.0k (down 147% from profit in 3Q 2021). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance. Price Target Changed • Nov 16
Price target decreased to €10.50 Down from €12.50, the current price target is an average from 2 analysts. New target price is 17% above last closing price of €9.00. Stock is down 46% over the past year. The company is forecast to post a net loss per share of €0.59 next year compared to a net loss per share of €0.63 last year. Reported Earnings • Sep 01
Second quarter 2022 earnings released: EPS: €0.30 (vs €0.002 loss in 2Q 2021) Second quarter 2022 results: EPS: €0.30. Revenue: €16.6m (up 206% from 2Q 2021). Net loss: €4.61m (loss widened €4.60m from 2Q 2021). Over the next year, revenue is forecast to grow 48%, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Annonce • Aug 31
VITA 34 AG Revises Earnings Guidance for the Financial Year 2022 VITA 34 AG revised earnings guidance for the financial year 2022. For the year, the company adjusting the forecast ranges for consolidated sales to EUR 65 to EUR 72 million (previously: EUR 68 to EUR 75 million). Annonce • Aug 24
VITA 34 AG to Report Q2, 2022 Results on Aug 30, 2022 VITA 34 AG announced that they will report Q2, 2022 results on Aug 30, 2022 Major Estimate Revision • Jun 07
Consensus EPS estimates fall by 85% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €73.4m to €68.9m. Losses expected to increase from €0.27 per share to €0.50. Healthcare industry in Germany expected to see average net income growth of 6.5% next year. Consensus price target down from €14.00 to €13.00. Share price rose 2.3% to €11.35 over the past week. Reported Earnings • Jun 02
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2022 results: €0.18 loss per share (down from €0.01 loss in 1Q 2021). Revenue: €15.5m (up 188% from 1Q 2021). Net loss: €2.81m (loss widened €2.77m from 1Q 2021). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 103%, compared to a 4.8% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Annonce • May 25
VITA 34 AG to Report Q1, 2022 Results on May 31, 2022 VITA 34 AG announced that they will report Q1, 2022 results on May 31, 2022 Reported Earnings • May 02
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: €0.63 loss per share (down from €0.37 profit in FY 2020). Revenue: €28.4m (up 42% from FY 2020). Net loss: €3.67m (down 343% from profit in FY 2020). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is expected to shrink by 17% compared to a 5.9% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Annonce • May 02
Vita 34 Ag Provides Revenue Guidance for the Financial Year 2022 VITA 34 AG provided revenue guidance for the financial year 2022. For the year, the company expects consolidated revenues of between EUR 68 million and EUR 75 million for the full year 2022 (2021: EUR 28.4 million). Price Target Changed • Apr 27
Price target increased to €25.00 Up from €19.10, the current price target is provided by 1 analyst. New target price is 109% above last closing price of €11.95. Stock is down 29% over the past year. The company is forecast to post earnings per share of €0.46 for next year compared to €0.37 last year. Price Target Changed • Dec 18
Price target increased to €21.10 Up from €19.10, the current price target is an average from 2 analysts. New target price is 35% above last closing price of €15.60. Stock is up 27% over the past year. The company is forecast to post earnings per share of €0.46 for next year compared to €0.37 last year. Reported Earnings • Nov 12
Third quarter 2021 earnings released: EPS €0.14 (vs €0.18 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: €5.82m (up 7.4% from 3Q 2020). Net income: €575.0k (down 23% from 3Q 2020). Profit margin: 9.9% (down from 14% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Reported Earnings • Sep 01
Second quarter 2021 earnings released The company reported a soft second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: €5.44m (up 11% from 2Q 2020). Net loss: €12.0k (down 102% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has increased by 3% per year. Major Estimate Revision • Jun 08
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast fell from €22.0m to €21.8m. EPS estimate rose from €0.47 to €0.52. Net income forecast to grow 92% next year vs 92% growth forecast for Healthcare industry in Germany. Consensus price target of €19.10 unchanged from last update. Share price was steady at €17.05 over the past week. Annonce • Jun 02
VITA 34 AG (XTRA:V3V) entered into a Business Combination Agreement to acquire Polski Bank Komórek Macierzystych S.A. (WSE:BKM) (PKBM) from AOC Health GmbH, Jakub Baran, Tomasz Baran and others for approximately PLN 840 million. VITA 34 AG (XTRA:V3V) entered into a Business Combination Agreement to acquire Polski Bank Komórek Macierzystych S.A. (WSE:BKM) (PKBM) from AOC Health GmbH, Jakub Baran, Tomasz Baran and others for approximately PLN 840 million on May 31, 2021. Transaction to be carried out by way of a contribution in kind at an exchange of 1.3 new Vita 34 shares in exchange for one (1) share of PBKM. Under the transaction, AOC Health GmbH will sell 5.743221 million shares representing 62.4% stake, Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. will sell 1.282201 million shares representing 13.93% stake and Jakub Baran will sell 0.395875 million shares representing 4.3% stake. Major PBKM shareholders have already agreed to contribute to Vita 34 a total of 6.363170 million PBKM shares (representing approximately 69.13% of the current share capital of PBKM). The combined Group will be listed on the Frankfurt Stock Exchange, with Vita 34 as the listed parent company. These shareholders include (inter alia) AOC Health GmbH, Jakub Baran, President and Chief Executive officer of the PBKM Management Board, and Tomasz Baran, Vice President and Deputy Chief Executive officer of the PBKM Management Board.
The new Vita 34 shares to be issued under the Proposed Transaction shall be created by way of a capital increase in kind still to be resolved upon by Vita 34’s shareholders. For purposes of resolving the capital increase, Vita 34 will convene an extraordinary general meeting for July 13, 2021, with the ordinary annual general meeting originally scheduled for June 30, 2021 to be postponed and likely to take place in the fourth quarter of 2021. At the extraordinary general meeting, Vita 34’s share capital shall be increased by up to €12.280560 million against contribution in kind by issuing up to 12,280,560 no-par value registered shares. Completion of the Exchange Offer is subject to a number of conditions, including the achievement of a minimum acceptance level of 95% of PBKM’s outstanding shares and the absence of any material adverse change and no material adverse infringements occurring at PBKM. Transaction has been approved by the Supervisory Board of Vita 34 AG. The Management Board PBKM intends to support the Proposed Transaction and recommend to the PBKM shareholders to accept the Exchange Offer.
Transaction is expected to complete by the end of October 2021. VITA 34 AG appointed ValueTrust Financial Advisors SE as an independent expert under the transaction. Reported Earnings • Jun 01
First quarter 2021 earnings released The company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: €5.38m (up 15% from 1Q 2020). Net loss: €38.0k (down 110% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Annonce • Jun 01
VITA 34 AG Provides Earnings Guidance for the Year 2021 VITA 34 AG maintained guidance for 2021. The Management Board maintains its guidance for the full fiscal year 2021 of Vita 34 AG (prior to the planned merger) published in the context of the Annual Report 2020. Major Estimate Revision • Apr 07
Consensus EPS estimates fall to €0.47 The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €22.3m to €22.0m. EPS estimate also fell from €0.61 to €0.47. Net income forecast to grow 26% next year vs 16% growth forecast for Healthcare industry in Germany. Consensus price target up from €20.00 to €21.00. Share price rose 2.3% to €15.25 over the past week. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS €0.37 (vs €0.18 in FY 2019) The company reported a solid full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: €20.1m (flat on FY 2019). Net income: €1.51m (up 104% from FY 2019). Profit margin: 7.5% (up from 3.7% in FY 2019). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 10
New 90-day high: €13.95 The company is up 11% from its price of €12.60 on 11 November 2020. The German market is also up 11% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Healthcare industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.83 per share. Is New 90 Day High Low • Jan 23
New 90-day high: €13.05 The company is up 4.0% from its price of €12.55 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.88 per share. Annonce • Dec 19
VITA 34 AG, Annual General Meeting, Jun 30, 2021 VITA 34 AG, Annual General Meeting, Jun 30, 2021. Price Target Changed • Nov 26
Price target raised to €17.50 Up from €15.00, the current price target is an average from 2 analysts. The new target price is 39% above the current share price of €12.55. As of last close, the stock is down 4.9% over the past year. 
